SAN FRANCISCO—February 6, 2015—Fluoresentric, Inc. today announced its selection to present its disruptive XCR™ technology at the Molecular Med Tri-Con 2015 on Feb. 18th. The company is among 12 presenters to pitch their company’s value proposition to a panel of industry leaders at the Inaugural Swimming with the Sharks competition. Presenters will be judged on clinical utility, investor readiness, and healthcare impact. The top place winner will receive recognition as the “2015 Tri-Con Most Promising Company” along with cash incentives.
“We are pleased to be invited to make our case to such a distinguished industry group,” states William Olson, Fluoresentric CEO. “XCR™ is positioned to greatly improve molecular diagnostics in the lab, as well as at point-of-care. The great news is our assays are available now and they work with ubiquitous PCR hardware in use today.”
XCR™ combines the best of PCR and isothermal methods with none of their limitations. It is as much as 10-fold faster than PCR and has no primer dimer, low cost reagents, low cost portable instrumentation, high multi-plex, and simple sample prep: resistance to PCR inhibitors.
The current standard for nucleic acid amplification requires 40 to 60 minutes, an unacceptable time for several critical testing areas, particularly at the Point of Care, where testing must be completed in less than 20 minutes to get a clinically actionable result. As a new approach to nucleic acid amplification testing (NAAT), XCR™ amplification and detection occurs in ~5 minutes with both DNA and RNA target nucleic acids. It eliminates amplification artifacts (e.g. primer-dimer) while dramatically reducing turnaround time, delivering a clinical result without compromise.
Sponsors for this inaugural event include Abbott Molecular, Elsevier, IBM, The Jackson Laboratory, Leica Biosystems, NanoString Technologies, Silicon Biosystems, and Singulex, among others.
About Fluoresentric, Inc.
Fluoresentric Inc. is a start-up chemistry company positioned to monetize its XCR™ technology portfolio globally. Initially started as a custom PCR assay Design Company recruited by Roche to support their LightCycler® thermalcycler, the company has designed over 1,000 PCR assays. Fluoresentric scientists are internationally recognized experts in the field of Real Time Polymerase Chain Reaction (PCR). The company’s XCR™ technology is positioned to dramatically trim test times, reduce healthcare costs, with a vision to deliver hyper-accurate molecular diagnostics testing at Point of Care.
Help employers find you! Check out all the jobs and post your resume.
